BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32897960)

  • 1. Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma.
    Bennett JA; Safdar N; Segal JP; Lastra RR; Oliva E
    Int J Gynecol Pathol; 2021 Mar; 40(2):156-164. PubMed ID: 32897960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features.
    Villatoro TM; Ma C; Pai RK
    Hum Pathol; 2020 May; 99():53-61. PubMed ID: 32222462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression.
    Huang SC; Ng KF; Yeh TS; Cheng CT; Chen MC; Chao YC; Chuang HC; Liu YJ; Chen TC
    Histopathology; 2020 Aug; 77(2):250-261. PubMed ID: 32343857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
    Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
    Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SWI/SNF protein and claudin-4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum.
    Chaudet K; Kem M; Lerwill M; Young RH; Mino-Kenudson M; Agaimy A; McCluggage WG; Oliva E
    Histopathology; 2020 Aug; 77(2):231-239. PubMed ID: 32268438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
    Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
    PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma.
    Ge H; Xiao Y; Qin G; Gu Y; Cai X; Jiang W; Tu X; Yang W; Bi R
    Diagn Pathol; 2021 Feb; 16(1):12. PubMed ID: 33541386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.
    Schaefer IM; Agaimy A; Fletcher CD; Hornick JL
    Mod Pathol; 2017 Apr; 30(4):539-548. PubMed ID: 28084340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract.
    Agaimy A; Bertz S; Cheng L; Hes O; Junker K; Keck B; Lopez-Beltran A; Stöckle M; Wullich B; Hartmann A
    Virchows Arch; 2016 Sep; 469(3):321-30. PubMed ID: 27339451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SWI/SNF Alterations in Squamous Bladder Cancers.
    Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
    Tessier-Cloutier B; Coatham M; Carey M; Nelson GS; Hamilton S; Lum A; Soslow RA; Stewart CJ; Postovit LM; Köbel M; Lee CH
    J Pathol Clin Res; 2021 Mar; 7(2):144-153. PubMed ID: 33125840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID1A, BRG1, and INI1 deficiency in undifferentiated and dedifferentiated endometrial carcinoma: a clinicopathologic, immunohistochemical, and next-generation sequencing analysis of a case series from a single institution.
    Korentzelos D; Elishaev E; Zhao C; Jones MW; Soong TR; Lesnock J; Orellana T; Zeccola A; Diamantopoulos LN; Wald AI; Bhargava R
    Hum Pathol; 2022 Dec; 130():65-78. PubMed ID: 36252860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
    Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
    Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.